Immunotherapy in Melanoma | Specialty

Focus Moves to Earlier Settings in Melanoma

February 12th 2018

Novel systemic therapies in the neoadjuvant and adjuvant settings have shown promising outcomes for locally advanced melanoma and may reduce the proportion of patients who need complete lymphadenectomy.

Updates in Targeted Combination Therapies for Melanoma

February 9th 2018

With the advent of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in melanoma physicians are no longer using BRAF inhibitors alone, but rather in combination with MEK inhibitors due to the improved efficacy.

Binimetinib/Encorafenib Positive OS Data Released as FDA Weighs Melanoma Approval

February 6th 2018

Treatment with encorafenib and binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

Complete Lymph Node Dissection Not Superior to Surveillance in Melanoma

January 31st 2018

Daniel Coit, MD, discusses clinical findings with complete lymph node dissection and the evolution of surgery in the melanoma landscape.

Novel Combinations Continue to Advance Melanoma Field

January 29th 2018

Mario Sznol, MD, discusses overall advances in the field of melanoma, as well as novel treatments with the potential to change the treatment paradigm.

Weber Shares Insight on Future of Immunotherapy in Melanoma

January 26th 2018

Jeffrey S. Weber, MD, PhD, discusses the future of immunotherapy in the treatment of melanoma.

Dr. Coit on the Evolving Role of Surgery in Patients With Melanoma

January 25th 2018

Daniel G. Coit, MD, FACS, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of surgery in treating patients with melanoma.

Dr. Kluger on Systemic Management of Melanoma With Brain Metastases

January 25th 2018

Harriet Kluger, MD, professor of medicine, associate cancer center director for education and training, deputy section chief, Medical Oncology, Yale Cancer Center, discusses the progression of treatment for patients with melanoma who have brain metastases.

CMV Vaccine Falls Short in Phase III Trial

January 23rd 2018

ASP0113, an investigational DNA vaccine developed for cytomegalovirus-seropositive hematopoietic stem cell transplant patients, has failed to meet its primary and secondary endpoints.

Ipilimumab Approved in Europe for Pediatric Melanoma

January 23rd 2018

Ipilimumab has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.

Dr. Weber on Growing Costs With Triplet and Four-Drug Regimens in Melanoma

January 17th 2018

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Dr. Kudchadkar on Immunotherapy in Merkel Cell Carcinoma

January 10th 2018

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses immunotherapy in Merkel cell carcinoma.

Dr. Landi Discusses the Importance of Screening in Melanoma

January 9th 2018

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the importance of screening in melanoma.

Adjuvant Pembrolizumab Improves RFS in Melanoma

January 9th 2018

Adjuvant pembrolizumab reduced the risk of recurrence by 43% in patients with stage III resected high-risk melanoma.

Dr. Carvajal Discusses the Biology of Extracutaneous Melanoma

January 4th 2018

Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.

Dr. Sonpavde on the Potential for Immunotherapy in Penile Cancer

January 3rd 2018

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

Dr. Ott Discusses Ipilimumab and Nivolumab in Melanoma

January 2nd 2018

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.

The Future of Treatment for Nonmetastatic CRPC

December 28th 2017

Nonmetastatic CRPC: The Changing Landscape of Treatment

December 28th 2017

Enzalutamide in the Context of Nonmetastatic CRPC

December 28th 2017